• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Watch Beaten-Down Drug Companies, Hospitals in 2017

There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.
By JIM COLLINS
Dec 29, 2016 | 04:00 PM EST
Stocks quotes in this article: PFE, MRK, JNJ, VRX, ENDO, PRGO, MYL, THC, CYH

Following on from my column yesterday, here are a few sectors that have produced multiple laggards in this year's rally. The Trump Jump has not been kind to every sector, especially certain health-care subsectors. Questions about pricing and reimbursement are dogging stocks of pharmaceutical consolidators and some hospital chains. The Affordable Care Act is DOA, in my opinion, but what stands in its place is still to be discovered. The blue chips like Pfizer (PFE) , Merck (MRK) and Johnson & Johnson (JNJ) have lagged since the election but not so much that it would dent one's portfolio. And all three offer solid yields for long-term holders.

No, the great pain -- and, it must be said, potential opportunity, for the bottom-fishers among the investment community -- has come from companies whose very business models are under pressure from threats to control pharmaceutical pricing and deregulate Obamacare. I'm not recommending these stocks, rather presenting them as potential diamonds in the rough (and in some cases, especially Valeant Pharmaceuticals (VRX) , 2016 was terribly rough) for those investors looking for mean-reversion trades.

It all seemed so simple. Buy drug companies, harvest operating efficiencies and benefits of scale and watch profits drop to the bottom line as new management pushes through price increases on the acquired products. Well, 2016 showed us that it's not that simple. Want proof? Run a four-stock comparison with Valeant, Endo International (ENDO) , Perrigo (PRGO) and Mylan (MYL) . Their year-to-date performances are certainly enough to send one reaching for the medicine cabinet: VRX down 86%, ENDP down 74%, PRGO down 43% and MYL down 35%.

Is it possible, however, that the often-misplaced and occasionally hilarious, sanctimonious faux populism of election season is just going to die away like a fading Clinton/Kaine yard sign? Personally, I hope so, and if it does that will give these companies a chance to tune their business models to a reality in which price increases are not a given and margins must be won. Also, as Real Money Godfather Jim Cramer has mentioned many times, companies that grow only via acquisition must be scrutinized very closely when it comes to purchase accounting. Very, very, very closely. It is always the elephant in the room when it comes to owning any of these stocks, and certainly for VRX it has been the company's Achilles' heel. So, the key for 2017 is for these managements to focus on internal restructuring and sustaining profitability in an environment in which acquisitions are not so easy.

Similarly, for companies like Tenet Healthcare (THC) (down 51%) and Community Health Systems (CYH) (down 78%), the ACA's colossal failure and current status in mid-death spiral has produced nauseating year-to-date stock performances. But -- the market is clearly asking -- what if the alternative to Obamacare is actually worse? That's where we stand today. It's a scary position, and much like the specialty pharma companies above, a key part of the Tenet and Community Health Systems growth stories has always been acquisitions. The Obama administration's misguided, narrowly-focused and extremely selective prosecutions of antitrust statutes have affected health-care broadly. But I don't think that's coloring sentiment among health-system managements as we head into 2017. I think they are more concerned about who is going to pay them to care for their patients and where those patients will come from. Until these basic questions are answered, it's just not a good time to be consolidating hospitals. Again, though, the stocks to buy in 2017 would be ones where management has committed to internal restructuring in an uncertain environment, not focusing on growth through acquisition.

So, in those two health-care sectors, pharmaceutical consolidators and some hospital chains, there's no "screaming buy," but the stock prices have been so horrible that I intend to educate myself on the fundamentals of the six individual companies I mentioned as potential 2017 trading ideas. In tomorrow's column, I'll give two names that are even more beaten down than Valeant ... but much closer to a "sure thing" for trading profitably in the New Year.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

2 More Covered Call Opportunities That Are Calling Investors

Bret Jensen
Jan 25, 2021 8:30 AM EST

Here are options plays involving promising small-caps Clearside Biomedical and Mustang Bio.

Trade Carefully With Soaring Gritstone Oncology

Bruce Kamich
Jan 21, 2021 8:16 AM EST

The history we are concerned about is the past couple of weeks.

UnitedHealth Group Charts Appear Toppy Ahead of Earnings

Bruce Kamich
Jan 19, 2021 8:53 AM EST

The technical indicators of the health benefits concern are not sending strong signals at present.

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:35 AM EST CHRIS VERSACE

    Another Big Winner for Stocks Under $10

    We're ringing the register Tuesday morning.
  • 08:05 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/26/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 09:52 AM EST GARY BERMAN

    INDU/DIA 20 DMA

    Fibocall: The DIA has the 20 DMA @ 307.81 and w...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login